Cabaletta Bio (CABA) EBITDA (2018 - 2025)

Cabaletta Bio's EBITDA history runs 8 years deep, the most recent figure standing at -$41.9 million for Q4 2025.

• In Q4 2025, EBITDA fell 28.63% year-over-year to -$41.9 million; the TTM figure through Dec 2025 stood at -$167.8 million (down 44.8% YoY), while the FY2025 annual figure was -$167.8 million, down 44.8% from the prior year.
• EBITDA was -$41.9 million for Q4 2025 at Cabaletta Bio, up from -$44.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$9.7 million in Q1 2021 to a low of -$45.1 million in Q2 2025.
• Historically, EBITDA has averaged -$22.5 million across 5 years, with a median of -$16.1 million in 2023.
• The sharpest annual moves came in 2022 and 2024: EBITDA climbed 1.51% in 2022, then tumbled 90.43% in 2024.
• A 5-year view of EBITDA shows it stood at -$13.9 million in 2021, then declined by 11.87% to -$15.5 million in 2022, then plunged by 33.8% to -$20.8 million in 2023, then slumped by 56.83% to -$32.6 million in 2024, then declined by 28.63% to -$41.9 million in 2025.
• The last three EBITDA figures came in at -$41.9 million (Q4 2025), -$44.8 million (Q3 2025), and -$45.1 million (Q2 2025), per Business Quant data.